UveitisNCT05727540
The Cohort Study of Uveitis Patients
An observational study of Uveitis, run by Zhongshan Ophthalmic Center, Sun Yat-sen University at 1 site in China.
Trial summary
This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Uveitis
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 20 Feb 2023to 31 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population are adult uveitis patients.
Who may be able to join
- The diagnosis is uveitis; The agreement of enrolling this study;
Who cannot join
- Uveitis during the first month after any intraocular surgery; <18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Cohort Study of Uveitis Patients Based on Real-world Data
This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.
- Conditions
- Uveitis
- Medical subject headings
- Uveitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Noninfectious uveitis | Not described | |
| Infectious uveitis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 12 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Measured: 12 months post-treatment
Secondary outcomes (27)
Best corrected visual acuity
Best corrected visual acuity
Measured: 1 month post-treatment
Best corrected visual acuity
Best corrected visual acuity
Measured: 3 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Measured: 6 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Measured: 12 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Measured: 24 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Measured: 36 months post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 1 month post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 3 months post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 6 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 12 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 24 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Measured: 36 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 1 month post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 3 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 6 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 12 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 24 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Measured: 36 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 1 month post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 3 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 6 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 24 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Measured: 36 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Measured: 3 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Measured: 6 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Measured: 24 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Measured: 36 months post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2023
- Study start20 Feb 2023
- Primary completion31 Mar 2026
- Study completion31 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for UveitisStudies of the same condition, open and under way.
- More trials run by Zhongshan Ophthalmic Center, Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05727540
- Sponsor's protocol ID
- 2022KYPJ227
- Status last verified
- Sep 2026
- First submitted
- 11 Jan 2023
- Last updated
- 24 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Cohort Study of Uveitis Patients Based on Real-world Data
- ClinicalTrials.gov ID
- NCT05727540
- Acronym / sponsor ID
- 2022KYPJ227
- Conditions
- Uveitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 20 Feb 2023 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 31 May 2026 (actual)
- First posted
- 14 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Noninfectious uveitis | – | – |
| Infectious uveitis | – | – |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population are adult uveitis patients.
Key inclusion criteria (1 listed)
- The diagnosis is uveitis; The agreement of enrolling this study;
Key exclusion criteria (1 listed)
- Uveitis during the first month after any intraocular surgery; <18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 12 months post-treatment
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
Time frame: 12 months post-treatment
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
27 secondary outcomes
Best corrected visual acuity
Time frame: 1 month post-treatment
Best corrected visual acuity
Time frame: 3 months post-treatment
Best corrected visual acuity
Time frame: 6 months post-treatment
Best corrected visual acuity
Time frame: 12 months post-treatment
Best corrected visual acuity
Time frame: 24 months post-treatment
Best corrected visual acuity
Time frame: 36 months post-treatment
The number of intraocular pressure
Time frame: 1 month post-treatment
The number of intraocular pressure
Time frame: 3 months post-treatment
The number of intraocular pressure
Time frame: 6 months post-treatment
The number of Intraocular pressure
Time frame: 12 months post-treatment
The number of Intraocular pressure
Time frame: 24 months post-treatment
The number of Intraocular pressure
Time frame: 36 months post-treatment
Central retinal thickness
Time frame: 1 month post-treatment
Central retinal thickness
Time frame: 3 months post-treatment
Central retinal thickness
Time frame: 6 months post-treatment
Central retinal thickness
Time frame: 12 months post-treatment
Central retinal thickness
Time frame: 24 months post-treatment
Central retinal thickness
Time frame: 36 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 1 month post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 3 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 6 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 24 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 36 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
Time frame: 3 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
Time frame: 6 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
Time frame: 24 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
Time frame: 36 months post-treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
Related trials for Uveitis
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
Not yet recruiting
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
RecruitingObservational study
A Study of Uveitis in Children <18 Years of Age
Uveitis
Active, not recruitingPhase 2
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative
RecruitingPhase 1
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Non Infectious Uveitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uveitis, run by Zhongshan Ophthalmic Center, Sun Yat-sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system (time frame: 12 months post-treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.